NS-1209 | CAS# 245063-59-6 | Antiepileptic

MedKoo Cat#: 522540 | Name: NS-1209

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NS-1209 is an antiepileptic drug candidate currently under clinical trials. Epilepsy is one of the most common serious neurological disorders in adults, affecting approximately 50 million people worldwide at a total annual cost, in Europe, of approximately 15.5 billion Euros.

Chemical Structure

NS-1209

CAS#245063-59-6

Theoretical Analysis

MedKoo Cat#: 522540

Name: NS-1209

CAS#: 245063-59-6

Chemical Formula: C24H28N4O7S

Exact Mass: 516.1679

Molecular Weight: 516.57

Elemental Analysis: C, 55.80; H, 5.46; N, 10.85; O, 21.68; S, 6.21

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

NS-1209; NS 1209; NS1209; 245063-59-6; SPD-502; SPD502; SPD 502

IUPAC/Chemical Name

(R,Z)-2-(((5-(4-(N,N-dimethylsulfamoyl)phenyl)-8-methyl-2-oxo-1,2,6,7,8,9-hexahydro-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene)amino)oxy)-4-hydroxybutanoic acid

InChi Key

CFJRSKULEDUDKL-HXUWFJFHSA-N

InChi Code

InChI=1S/C24H28N4O7S/c1-27(2)36(33,34)15-6-4-14(5-7-15)17-12-18-21(19-13-28(3)10-8-16(17)19)25-23(30)22(18)26-35-20(9-11-29)24(31)32/h4-7,12,20,29H,8-11,13H2,1-3H3,(H,31,32)(H,25,26,30)/t20-/m1/s1

SMILES Code

O=C(O)[C@H](O/N=C1C2=C(C(C3)=C(CCN3C)C(C4=CC=C(C=C4)S(N(C)C)(=O)=O)=C2)NC/1=O)CCO

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 516.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Mula M. Emerging drugs for focal epilepsy. Expert Opin Emerg Drugs. 2013 Mar;18(1):87-95. doi: 10.1517/14728214.2013.750294. Epub 2012 Nov 26. Review. PubMed PMID: 23176519. 2: Perucca E. What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate. Epilepsia. 2009 Dec;50 Suppl 12:49-50. doi: 10.1111/j.1528-1167.2009.02366.x. Review. PubMed PMID: 19941524. 3: Landmark CJ, Johannessen SI. Modifications of antiepileptic drugs for improved tolerability and efficacy. Perspect Medicin Chem. 2008 Feb 14;2:21-39. PubMed PMID: 19787095; PubMed Central PMCID: PMC2746576. 4: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Mar;26(2):129-61. PubMed PMID: 15071612.